甲尼达诱导的脑病变和多神经病变
Partha Sahu1, Nivedita Sharma2, Prasan Kumar Panda3
1General Medicine (ID Division), All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
BMJ case reports
|April 22, 2025
概括
甲尼达可以引起严重的神经副作用,如外围神经病变和脑病变,特别是在高剂量或长期使用时. 及时停止药物可以导致显著的症状改善.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 甲尼达是一种有效的抗生素,但长期或高剂量治疗可能会导致严重的副作用.
- 甲尼达诱导的神经毒性,包括外围神经病变和脑病变,可以使人衰弱.
研究的目的:
- 报告在甲尼达治疗后出现严重的神经病变的病例.
- 为了突出认识到甲尼达诱导的神经毒性的重要性.
主要方法:
- 一个中年男性的案例研究,他因肝脏而接受高剂量的甲尼达治疗.
- 神经学评估包括神经传导研究 (NCS) 和磁共振成像 (MRI).
主要成果:
- 患者患有肌痛性关节障碍,动力不良的步态,以及与外围神经病变相一致的感觉丧失.
- NCS证实了轴突神经病变,MRI显示T2/FLAIR强度过高表明有毒脑病变.
- 在停止服用美特罗尼达后,症状显著改善.
结论:
- 高剂量或长时间的甲尼达治疗可能会导致严重的神经损伤,包括外围神经病变和脑病变.
- 临床医生应保持对长期或高剂量甲尼达治疗的患者神经毒性的警.
- 早期识别和停止使用甲尼达对于症状恢复至关重要.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
123
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
123
Antiepileptic Drugs: Glutamate Antagonists
246
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
246
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
184
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
184
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
96
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
96
Antiepileptic Drugs: GABAergic Pathway Potentiators
259
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
259


